Stay at the forefront of cardiology by being the first to see the latest scientific breakthroughs at five featured Late-Breaking Clinical Trial sessions.

ACC.13 Opening Showcase and Late-Breaking Clinical Trials
Session 300
Saturday, March 9, 8 – 10:10 a.m.
South, Esplanade Ballroom

• Final Results of Randomized Trial of Left Atrial Appendage Closure Versus Warfarin for Stroke/Thromboembolic Prevention in Patients with Non-Valvular Atrial Fibrillation (PREVAIL)
• HPS2-THRIVE: Randomized Comparison Of Extended-Release (ER) niacin/laropiprant 2g Daily Versus Placebo in 25,673 Patients At High Risk Of Occlusive Vascular Events

Late-Breaking Clinical Trials II: Interventional
Session 301
Sunday, March 10, 8 – 9:30 a.m.
South, Esplanade Ballroom

• Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome
• A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis who are not Candidates for Surgery: PARTNER 2, Cohort B Outcomes
• One-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the NOBORITM Biolimus-Eluting versus XIENCETM/PROMUSTM Everolimus-eluting Stent Trial (NEXT)
• Comparison of DK crush versus culotte stenting for unprotected distal left main bifurcation lesions: Results from a multicenter, randomized, prospective DKCRUSH-III study
• The Main Results of the CHAMPION PHOENIX Trial

Late-Breaking Clinical Trials III: Chronic CAD/Stable Ischemic Heart Disease and Acute Coronary Syndromes
Session 302
Sunday, March 10, 10:45 a.m. – 12:15 p.m.
South, Esplanade Ballroom

• The STREAM Trial
• Early Administration of Eplerenone in Patients with Acute Myocardial Infarction Without Heart Failure: Results of the Randomized, Double-Blind, Placebo-Controlled REMINDER Trial
• Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes Trial
• Randomized Comparison of High-dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy
• Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina: Results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina (TERISA) randomized clinical trial

Late-Breaking Clinical Trials IV: General Cardiology
Session 303
Monday, March 11, 8 – 9:30 a.m.
South, Esplanade Ballroom

• Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis
• A Randomized Trial to Compare Percutaneous Coronary Intervention between Massachusetts Hospitals With Cardiac Surgery On-Site and Community Hospitals Without Cardiac Surgery On-Site
• The German Off-Pump Coronary Artery Bypass Grafting in Elderly Patients (GOPCABE) Study
• CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 year
• PRAGUE-6 Trial: Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery in Patients With EuroSCORE ≥6

Late-Breaking Clinical Trials V: Heart Failure
Session 304
Monday, March 11, 10:45 a.m. – 12:15 p.m.
South, Esplanade Ballroom

• The St Vincent’s Screening To Prevent Heart Failure Study: Impact of Natriuretic Peptide Guided Screening and Treatment on Long-Term Prevalence of Left Ventricular Dysfunction, Heart Failure and Cardiovascular Events
• Digoxin Reduces 30-Day All-Cause Hospital Admission in Ambulatory Older Patients with Chronic Heart Failure and Reduced Ejection Fraction
• The ASTRONAUT Study: Aliskiren Trial On Acute Heart Failure Outcomes
• Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial
  
  
  

Browse the ACC.13 eMeeting Planner App or Online Planner to learn more. Search “ACC.13” in your app store, view the online Program Planner on your computer or learn more about these tools and how they can help you Plan Your ACC.13.